Duncan Gregory Scott 4

What Happened
Duncan Gregory Scott, a director of CorMedix Inc. (CRMD), received a grant of 30,453 restricted stock units (RSUs) on January 26, 2026. The Form 4 reports the acquisition as an award (transaction code A) at $0.00 per unit (total reported value $0). Each RSU represents the right to receive one share of CorMedix common stock and will vest in full on January 26, 2027, subject to continued service on the vesting date.

Key Details

• Transaction date: 2026-01-26 (Form 4 filed 2026-01-27). Filing appears timely (Form 4 filed within required reporting window).
• Transaction type/code: Award/Grant (A).
• Amount: 30,453 RSUs; reported price $0.00 per unit (total reported value $0).
• Vesting: Units vest in full on 2027-01-26, subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnotes/remarks: F1 explains each RSU converts to one share at vesting; Exhibit 24.1 (Power of Attorney) is attached.

Context
RSU grants are a form of compensation, not an open-market purchase or sale. The reported $0.00 price reflects grant accounting in the Form 4; the economic value to the insider will depend on CorMedix’s share price at vesting and any applicable tax or withholding. Such awards are common for directors and reflect compensation rather than an immediate insider buy/sell signal.